Therics, Inc.

Therics, Inc., a Princeton-based biopharmaceutical company, is developing revolutionary reconstructive products and pharmaceutical dosage forms with a new-to-the-world design and fabrication process. The advent of TheriForm™ microfabrication technology represents a fundamental advance in tissue engineering and drug delivery. This unique three-dimensional printing process allows the conceptualization and realization of an array of sophisticated products, with structures and attributes that far exceed the capabilities of conventional manufacturing techniques. With TheriForm, it is now possible to design and develop much needed products that are simply too complex for traditional manufacturing processes, or that require a level of precision which cannot be achieved with any other technology.

TheriForm technology provides a powerful tool for the creation of unique reconstructive implants, including bone replacement products, as well as innovative acellular and cell-containing tissue scaffolds that can incorporate drugs and growth factors at specific sites, and in gradients, to enhance the development of functional tissue within the body. Similarly, TheriForm provides powerful competitive weapons for leading edge pharmaceutical and biotechnology companies in drug discovery, formulation development, manufacturing and marketing. Based upon three-dimensional printing technology developed at the Massachusetts Institute of Technology, TheriForm technology and products are protected by a broad portfolio of strong patents, including an exclusive license from MIT for the worldwide health care market.